0000904454-18-000183.txt : 20180216
0000904454-18-000183.hdr.sgml : 20180216
20180216164817
ACCESSION NUMBER: 0000904454-18-000183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180214
FILED AS OF DATE: 20180216
DATE AS OF CHANGE: 20180216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haskel William M.
CENTRAL INDEX KEY: 0001524372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36066
FILM NUMBER: 18621850
MAIL ADDRESS:
STREET 1: ONE MEADOWLANDS PLAZA
CITY: EAST RUTHERFORD
STATE: NJ
ZIP: 07073
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001178711
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330960223
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: (617) 807-6600
MAIL ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc
DATE OF NAME CHANGE: 20090130
FORMER COMPANY:
FORMER CONFORMED NAME: NOVACEA INC
DATE OF NAME CHANGE: 20020724
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-02-14
0001178711
Paratek Pharmaceuticals, Inc.
PRTK
0001524372
Haskel William M.
C/O PARATEK PHARMACEUTICALS, INC.
75 PARK PLAZA, 4TH FLOOR
BOSTON
MA
02116
0
1
0
0
Sr. VP, Sec. & General Counsel
Common Stock
2018-02-14
4
A
0
27000
0
A
62458
D
Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2018, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.
/s/ William M. Haskel
2018-02-16